Nourish: $70 Million Series B Closed For Addressing Chronic Disease With AI-Based Nutrition Care

By Amit Chowdhry ● Yesterday at 9:01 PM

Nourish, a leading provider of nutrition counseling in the country, announced a $70 million Series B funding round, bringing total funding to $115 million. The funding round was led by J.P. Morgan Private Capital’s Growth Equity Partners, with participation from Thrive Capital, Index Ventures, Y Combinator, Maverick Ventures, BoxGroup, Atomico, G Squared, and Pinegrove.

What Nourish does: The company connects patients, dietitians, and insurance payers through a fully integrated virtual care platform, making it easy to access insurance-covered dietitian care for every major nutrition-related condition.

The company now serves hundreds of thousands of patients across all 50 states and employs over 3,000 W-2 RDs—the largest network in the country. Nourish partners with national commercial, Medicare, and Medicaid plans, covering hundreds of millions of lives, with 94% of patients paying $0 out of pocket.

Nourish’s app supports patients with AI-based meal tracking, wearable and lab integrations, recipes, and more. It also equips RDs with an AI copilot that automates note-taking, surfaces clinical insights, and eliminates administrative burden, enabling them to deliver best-in-class care.

Value Proposition: Nourish was created on a simple but urgent premise: nutrition-related chronic disease is the largest and most overlooked crisis in the world. Now a large percentage of Americans live with at least one chronic condition and nearly half have two or more. And nutrition-related cardiometabolic conditions like obesity, diabetes, and heart disease together account for the vast majority of the nation’s healthcare spend. Working with an RD is one of the most effective interventions available, but a very small percentage of eligible Americans use their covered benefits due to a lack of awareness and limited access. Nourish’s model is already delivering meaningful clinical results, with patients seeing major improvements in clinical markers such as A1C and LDL. And Nourish’s recently published data shows patients on GLP-1s like Ozempic lost 33% more weight when paired with a Nourish RD, while also reporting better medication adherence and reduced side effects.

Company founders: Nourish was created just over three years ago by three close friends who saw firsthand the power of food as medicine by working with an RD to address their own chronic conditions.

What the funding will be used for: The funding will accelerate product development, expand Nourish’s Registered Dietitian (RD) network, and deepen strategic partnerships across the healthcare ecosystem. Nourish will also continue to grow its team across all functions.

KEY QUOTES:

“We built Nourish to make healthcare radically better for millions of Americans — it’s the care we wanted ourselves during our own patient journeys. We wanted to build a patient-friendly healthcare system with lifestyle change and nutrition as a first-line treatment, not an afterthought. We’re combining cutting-edge AI with the best RD team in the country to deliver personalized care that actually works, at a fraction of the cost of traditional medicine. It is not only more effective and accessible, but also more human.”

Aidan Dewar, co-founder and CEO

“Our healthcare system is at an inflection point, with chronic disease rates and costs rising to unsustainable levels. Payers are under growing pressure to find scalable solutions that actually work. Nourish meets this need by addressing the root cause of chronic disease — giving payers a powerful new lever to improve outcomes, bend the cost curve, and deliver a care experience members love.”

Sam Perkins, co-founder, President and COO of Nourish

“Nourish is addressing one of our country’s most urgent challenges with a compelling outcomes-driven and AI-native approach. I’m excited to continue supporting a category-defining company like Nourish, with a unique blend of mission, vision, and measurable impact.”

Paris Heymann, Co-Managing Partner of J.P. Morgan Growth Equity Partners

Exit mobile version